Viral Genetics, based in San Marino, Calif., holds an exclusive option to acquire the rights to the intellectual property, which adds to a portfolio of IP the company had previously licensed from CU based on the work of M. Karen Newell Rogers, a professor of biology at the University of Colorado, Colorado Springs.
David Denkenberger and John Zhai, for a demonstration of an improved micro-channel heat management device for power plants, energy-efficient vehicles and buildings, and other industrial applications.To learn more about POC grants for renewable energy research, please visit the TTO website.
Conrad Stoldt and Se-Hee Lee, for work on improved performance of lithium-ion (Li+) batteries via solid-state nanostructuring.
Robert Erickson, for a project on ‘smart’ power electronics for photovoltaic panels that maximize the energy captured by each panel. This proposal was funded as a $50,000 proof of concept investment to Phobos Energy, a University of Colorado startup company based on technology from Dr. Erickson’s CU-Boulder lab.
A University of Colorado research team led by Dr. Lajos Gera has developed a compound that directly inhibits survivin and effectively retards skeletal growth of human prostate cancer. The compound is BKM1740, a bradykinin antagonist previously shown to suppress tumor growth, conjugated with bis-phosphonate, which targets the compound to bone. Dr. Gera has in vitro data showing that 2-10μM of BKM1740 is able to induce 20-80% apoptosis, respectively, in metastatic prostate cancer cells.$26.5 million [provided by HB 08-1001] can't compare to the kind of money that California, Massachusetts, Florida and others have already spent fostering biotech. But it is a cleverly designed program that has real potential to help emerging biotech companies -- as well as state researchers and institutions -- when they need it the most. Combined with a few more scientific recruiting coups, Colorado could start to realize its latent potential.Read the full report.
W3W3 radio talked with CU-Boulder's Hubert Yin about his work identifying potential treatments for pain which avoiding the side effects of morphine and other opioid drugs. Dave Allen, CU Associate Vice President for Technology Transfer, sat in on this inspiring interview.
A group of University of Colorado researchers led by Dr. Theodore Randolph have devised a technique to place a pharmaceutical substance into solution in an organic solvent in the form of a hydrophobic ion pair complex with an amphiphilic material. The resulting solution may then be subjected to gas antisolvent precipitation using a near critical or supercritical fluid to produce a precipitate of particles comprising the pharmaceutical substance. Particles may be produced with a relatively narrow size distribution in a variety of sizes, permitting flexibility in preparing particles for effective utilization in a variety of pharmaceutical applications.
